Private Advisor Group LLC lifted its position in shares of Abbott Laboratories (NYSE:ABT – Free Report) by 47.6% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 143,495 shares of the healthcare product maker’s stock after buying an additional 46,264 shares during the quarter. Private Advisor Group LLC’s holdings in Abbott Laboratories were worth $14,182,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Tyche Wealth Partners LLC raised its stake in Abbott Laboratories by 17.1% during the third quarter. Tyche Wealth Partners LLC now owns 12,827 shares of the healthcare product maker’s stock worth $1,268,000 after purchasing an additional 1,871 shares during the period. Ieq Capital LLC boosted its holdings in Abbott Laboratories by 69.2% in the third quarter. Ieq Capital LLC now owns 323,960 shares of the healthcare product maker’s stock valued at $32,017,000 after acquiring an additional 132,501 shares during the last quarter. Focus Advisor Solutions LLC grew its position in Abbott Laboratories by 239.8% during the third quarter. Focus Advisor Solutions LLC now owns 84,329 shares of the healthcare product maker’s stock valued at $8,334,000 after acquiring an additional 59,515 shares during the period. Checchi Capital Advisers LLC grew its holdings in shares of Abbott Laboratories by 8.1% during the 3rd quarter. Checchi Capital Advisers LLC now owns 13,769 shares of the healthcare product maker’s stock worth $1,361,000 after purchasing an additional 1,033 shares during the period. Finally, OneAscent Family Office LLC raised its holdings in Abbott Laboratories by 42.7% in the third quarter. OneAscent Family Office LLC now owns 3,537 shares of the healthcare product maker’s stock valued at $350,000 after buying an additional 1,059 shares during the period. Hedge funds and other institutional investors own 75.18% of the company’s stock.
Top Abbott Laboratories Stories
Investors following ABT have been watching these stories:
- Positive Sentiment: Leerink Partners upgraded Abbott from “market perform” to “outperform” and set a $124 price target, citing a more favorable outlook for the company. The higher rating is a potential bullish catalyst. Article
- Positive Sentiment: Abbott initiated the VOYAGER CE trial of its investigational Encantor software-guided TAVI system for severe aortic stenosis. The technology is designed to improve valve deployment; successful development could strengthen Abbott’s cardiovascular device pipeline, though clinical and regulatory outcomes remain uncertain. Article
- Neutral Sentiment: Articles noting that ABT is up 1.3% since its last earnings report revisit the results and look to earnings estimates for clues, but provide no specific new estimate revisions or fresh financial results. Article
Analyst Ratings Changes
ABT has been the subject of a number of research reports. Robert W. Baird upped their price target on shares of Abbott Laboratories from $121.00 to $123.00 and gave the stock an “outperform” rating in a research report on Thursday, October 22nd. Royal Bank Of Canada lowered their price objective on shares of Abbott Laboratories from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Thursday, October 22nd. Leerink Partners upgraded shares of Abbott Laboratories from a “market perform” rating to an “outperform” rating and set a $124.00 price objective on the stock in a report on Thursday. Wells Fargo & Company increased their price target on Abbott Laboratories from $112.00 to $119.00 and gave the company an “overweight” rating in a report on Thursday, October 22nd. Finally, Wolfe Research raised Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 target price on the stock in a research report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and a consensus target price of $119.04.
Check Out Our Latest Research Report on Abbott Laboratories
Abbott Laboratories Stock Performance
Shares of ABT stock opened at $102.96 on Friday. The company has a quick ratio of 1.00, a current ratio of 1.45 and a debt-to-equity ratio of 0.57. The business has a 50 day moving average of $103.91 and a two-hundred day moving average of $101.66. The company has a market cap of $178.32 billion, a P/E ratio of 38.42, a PEG ratio of 1.81 and a beta of 0.54. Abbott Laboratories has a 52 week low of $81.97 and a 52 week high of $129.85.
Abbott Laboratories (NYSE:ABT – Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The healthcare product maker reported $1.42 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.42. The business had revenue of $13.01 billion during the quarter, compared to analyst estimates of $12.99 billion. Abbott Laboratories had a return on equity of 18.04% and a net margin of 9.75%. The business’s revenue for the quarter was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.30 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.52 EPS for the current year.
Abbott Laboratories Dividend Announcement
The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 16th. Investors of record on Thursday, October 15th were issued a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 2.4%. The ex-dividend date of this dividend was Thursday, October 15th. Abbott Laboratories’s dividend payout ratio is 94.03%.
Insider Transactions at Abbott Laboratories
In related news, EVP Mary Moreland sold 3,500 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The stock was sold at an average price of $116.00, for a total value of $406,000.00. Following the sale, the executive vice president directly owned 100,791 shares in the company, valued at $11,691,756. This trade represents a 3.36% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.46% of the stock is owned by company insiders.
Abbott Laboratories Profile
Abbott Laboratories is a global healthcare company that develops, manufactures and markets medical devices, diagnostic tests, nutritional products and branded generic medicines. Its products serve patients and healthcare professionals in hospitals, clinics and other care settings. Abbott’s offerings include the FreeStyle Libre continuous glucose monitoring system, cardiovascular and other medical devices, laboratory and rapid diagnostic tests, and nutrition brands such as Ensure and Similac. Its established pharmaceuticals business sells branded generic medicines in markets outside the United States.
Read More
- Five stocks we like better than Abbott Laboratories
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT – Free Report).
Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.
